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Abstract
Hydrogel-forming microneedle array patches (MAPs) have been proposed as viable clinical tools for patient monitoring pur-
poses, providing an alternative to traditional methods of sample acquisition, such as venepuncture and intradermal sampling.
They are also undergoing investigation in the management of non-melanoma skin cancers. In contrast to drug or vaccine delivery,
when only a small number of MAP applications would be required, hydrogel MAPs utilised for sampling purposes or for tumour
eradication would necessitate regular, repeat applications. Therefore, the current study was designed to address one of the key
translational aspects of MAP development, namely patient safety. We demonstrate, for the first time in human volunteers, that
repeat MAP application and wear does not lead to prolonged skin reactions or prolonged disruption of skin barrier function.
Importantly, concentrations of specific systemic biomarkers of inflammation (C-reactive protein (CRP); tumour necrosis factor-α
(TNF-α)); infection (interleukin-1β (IL-1β); allergy (immunoglobulin E (IgE)) and immunity (immunoglobulin G (IgG)) were
all recorded over the course of this fixed study period. No biomarker concentrations above the normal, documented adult ranges
were recorded over the course of the study, indicating that no systemic reactions had been initiated in volunteers. Building upon
the results of this study, which serve to highlight the safety of our hydrogelMAP, we are actively working towards CEmarking of
our MAP technology as a medical device.
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Introduction
Hydrogel-forming microneedle array patches (MAPs, Fig. 1)
are based on arrays of projections less than 1 mm in height
perpendicularly arranged upon a flat baseplate, where both the
projections and the baseplate are comprised of chemically
cross-linked hydrophilic polymer matrices [1]. Upon painless,
blood-free, skin insertion, the microneedles quickly swell
through uptake of interstitial fluid from the viable skin layers,
with the degree of cross-linking determining the rate and
extent of fluid uptake [1]. Diffusion of fluid through the swell-
ing needles leads to subsequent swelling of the baseplate.
Unlike conventional microneedle delivery systems for drugs
or vaccines, the agent to be delivered is not contained with the
matrix of hydrogel-forming MAPs. Instead, a separate drug-
containing layer is attached to the upper surface of the base-
plate. This means that drug dose is not limited to what can be
loaded into or coated on to, the microneedles themselves.
Upon swelling, a continuous, unblockable conduit between
the drug reservoir and the viable skin layers is created. We
have made extensive use of this system for transdermal deliv-
ery of high doses of both small molecules and macromolecu-
lar agents [1], with our data suggesting that appropriately
sized patches could be used to administer daily doses of tens
or hundreds of milligrammes per day in humans [2]. This
creates the possibility for a substantial expansion of the range
of types of drug that could be successfully delivered
transdermally.
Hydrogel-forming MAPs are removed from skin intact,
depositing no measurable amounts of polymer in the viable
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skin layers [1, 2]. While this is a potential advantage over
dissolving microneedle systems in terms of safety, it also
opens up the possibility of using such systems for extraction
of skin interstitial fluid. Interstitial fluid concentrations often
reflect free (unbound and hence pharmacologically active)
concentrations of drugs and exogenous substances in plasma.
In fact, tissue concentrations are usually more predictive of
clinical outcome than total (i.e. free + bound) plasma concen-
trations [3, 4]. Given the fact that interstitial fluid also contains
many endogenous biomarkers of health and disease, minimal-
ly invasive sampling without recourse to blood extraction
would present a range of important opportunities in diagnos-
tics, patient monitoring and wearable sensors. Indeed, we have
successfully used hydrogel-forming MAPs for detection of
glucose and caffeine in human volunteers [5]. Intact removal
of hydrogel-forming MAPs may also facilitate targeted, min-
imally invasive, photothermal (PTT) therapy of non-
melanoma skin cancers. In PTT, heating the tissue to be
destroyed to ≥ 43 °C yields protein denaturation and disrup-
tion of the cellular membrane, causing ablation of tumour
tissues [6–8]. We have recently loaded hydrogel-forming
MAPs with plasmonic gold nanorods. Irradiation of such
nanostructures with near-infrared light allows controllable lo-
cal heating of tissue into which the microneedles are inserted
[9, 10]. By using a lower molecular weight cross-linker, these
hydrogel-formingMAPs do not swell as extensively. As such,
the gold nanorods can be retained within the hydrogel struc-
ture during irradiation with near-infrared light to heat and treat
the skin lesion. Post-treatment, the microneedles are removed,
along with their gold nanorod cargo. This new development
presents advantages over systemic injection of the plasmonic
agents, where whole body dosing inevitably occurs.
The most common indication of conventional microneedle
systems is in vaccine administration [11, 12]. In such cases,
only a small number of applications would be necessary to
achieve the desired immunological effect. In contrast,
hydrogel-forming MAPs used in drug administration or pa-
tient diagnosis/monitoring will clearly be an everyday prod-
uct. Most drug substances must be administered regularly to
maintain a therapeutic effect, while patients with ongoing con-
ditions often require repetitive or continuous monitoring.
Even when used in management of non-melanoma skin can-
cers, several applications may be required for tumour eradica-
tion. Accordingly, hydrogel-forming MAPs must be shown to
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not only be capable of being reproducibly inserted into skin on
a routine basis but must also have a demonstrated high level of
safety.
Our hydrogel-forming MAP technology is based on aque-
ous blends of poly(methyl vinyl ether-co-maleic acid) and
poly(ethylene glycol) [13]. Upon drying in poly(dimethylsi-
loxane) microneedle moulds, the material is cross-linked by
esterification to yield microneedle arrays that are hard in the
dry state, but rapidly take up interstitial fluid upon skin inser-
tion [1, 2]. We have shown that such MAPs can be reproduc-
ibly inserted into their own skin by human volunteers, even
when the patch size is much greater than the 1–2 cm2 size
typical of microneedle systems [14–16]. We have also shown
that the material of these MAPs is biocompatible, has inherent
anti-microbial properties and does not support microbial
growth [1, 17, 18]. Endotoxin levels are below the US FDA
cutoffs for products intended for injection directly into the
circulatory or lymphatic systems and these MAPs can be sub-
jected to gamma irradiation without affecting their properties
[18]. Recently, we have shown that repeat insertion into
mouse skin in vivo, followed by subsequent retention for
24 h did not lead to disturbance in skin appearance, skin bar-
rier function or biomarkers of infection, immunity, inflamma-
tion or allergy [19]. While we have already shown on numer-
ous occasions that single applications of these MAPs cause no
adverse effects in humans [1, 14, 16, 20, 21], the vital next
step in translation of this technology is to now demonstrate,
for the first time, the safety of repeat application, with
prolonged wear, in human volunteers.
Materials and methods
Chemicals
Gantrez® S-97 BF, copolymer of methyl vinyl ether and ma-
leic acid (PMVE/MA) (molecular weight = 1,500,000 Da),
was provided by Ashland Speciality Ingredients, Surrey,
UK. Poly(ethylene glycol) (PEG, molecular weight =
10,000) was obtained from Sigma Aldrich, Steinheim,
Germany. All other chemicals used were of analytical reagent
grade.
MN patch preparation
Aqueous blends containing 20% w/w PMVE/MA and 7.5%
w/w PEG 10,000 Da were utilised to fabricate hydrogel-
forming MAPs. The blend (0.5 g) was poured into
microneedle moulds (11 rows × 11 rows of needles holes, per-
pendicular to the base and of conical shape, 600 μm in depth
with base width of 300 μm and 300 μm interspacing on a
0.49 cm2 area). These moulds were then centrifuged at
2150g for 15 min and dried at room temperature for 48 h.
The formed microneedle arrays were cross-linked by heating
at 80 °C for 24 h and the sidewalls formed by the moulding
process removed using a heated blade, as described previously
[1, 2]. MAPs were then prepared by attaching the microneedle
arrays to a 2 cm × 2 cm piece of Tegaderm™ adhesive dress-
ing (3M, Bracknell, UK) immediately before application to
the skin of volunteers, as shown in Fig. 2.
Volunteer recruitment
Healthy, young, human volunteers (males and females),
aged between 24 and 39 years, were recruited to partici-
pate in the study. The recruitment was carried out by
convenience sampling of the postgraduate student popula-
tion within the School of Pharmacy. An invitation letter
was circulated to the students until sufficient numbers of
participants were achieved. If willing to participate, then a
participant information leaflet was provided, along with a
brief eligibility questionnaire which had to be completed
before commencement of the study. Informed consent was
obtained in writing from each volunteer before the com-
mencement of the study. All volunteer-related data was
anonymised, stored in password-protected files on a fire-
walled server and was scheduled for destruction 2 years
after completion of the study. Only the researchers directly
involved in the study had access to the data. The exclu-
sion criteria were:
& Those who had an active medical condition, such as the
common cold, at the time of the study.
& Those with chronic medical conditions or any inflamma-
tory disease.
& Those who had any dermatological conditions, such as
acne, eczema or psoriasis.
& Those who had a known allergy or hypersensitivity
disorder.
Volunteers were asked to lead their normal life, without
taking excessive physical activity while the patches were in
place. Participants were also required to keep the MAP appli-
cation area dry during the period of wear. Furthermore, they
were asked not to apply any cosmetic or hygiene-related prod-
ucts to their upper arm during the study period.
Study protocol
The study was conducted in the Clinical Research Facility
Northern Ireland (NICRF) at Belfast City Hospital.
Volunteers were asked to arrive at pre-specified times so as
to allow MAP application, measurement of transepidermal
water loss (TEWL) blood sampling. MAPs were applied by
the researcher to a previously marked area on the volunteers’
upper arms. MAPs were applied every day for a period of
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5 days, with application alternating from one arm to the other,
such that if the upper right arm was the application site on day
1, the upper left arm was the application site on day 2 and so
on. Photographic records of the volunteers’ arms aided posi-
tioning of the MAPs at approximately the same sites on each
occasion.
Confirmation of MN insertion, interstitial fluid
absorption and swelling using optical coherence
tomography and microscopic imaging
Optical coherence tomography (OCT, VivoSight™ Topical
Multi-Beam OCT Handheld Probe, Michelson Diagnostics
Ltd., Kent, UK) was used to visualise MAP insertion into
human skin in vivo. To assess the penetration measurements,
quantification was performed using the imaging software
ImageJ® (National Institutes of Health, Bethesda, MD,
USA). The scale of the image files used was 1.0 pixel =
4.2 μm, thus allowing accurate measurements of penetration
depth to be made.
To visualise absorption of interstitial fluids by MAPs, mi-
croscope images (Leica EZ4W microscope, Leica, Wetzlar,
Germany) of the patches along with digital images of the
MAPs collected from volunteers were inspected.
Blood collection before and after the repeated
application of hydrogel-forming MN patches
Blood samples were withdrawn by the stuff nurse.
Approximately 10 mL volumes were collected from the
volunteers by standard venepuncture technique. The area
of the puncture was wiped with an alcohol swap before
withdrawal and a sticking plaster (Band-Aid™, Johnson
& Johnson, Maidenhead, UK) was applied over the area
of blood collection to prevent any further bleeding and
to keep the area clean. Blood samples were collected in
EDTA-containing blood collection Vacutainer® (Beckton
Dickinson, Swindon, UK) tubes. Blood samples were
collected at the beginning of the first day and the after-
noon of the fifth day, after the end of the last MAP
application. Samples were stored at 4 °C until proc-
essed. Plasma was collected by centrifugation of collect-
ed blood samples at 2000 rpm (2-16k Sigma lab
centrifuge, Sigma, Hamburg, Germany) at 4 °C for
15 min. Collected plasma was stored in pre-sterilised
Eppendorf tubes and stored at − 80 °C. All samples
were recorded on the Human Tissue Act database main-
tained by the Research and Enterprise Directorate at
Queen’s University Belfast according to the policy of
the university. All samples were destroyed once the
study was completed and, at that time, removed from
the database.
Fig. 3 Schematic representation
of the study design
Fig. 2 Hydrogel-forming
microneedle array patch (MAP)
design. Single microneedle array
(A); microneedle array attached to
the adhesive part of the
TegadermTM dressing to form
the MAP (B)
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Measurement of skin integrity before and after MN
patch application
TEWL measurements have been established as a routine meth-
od for evaluating the integrity of skin which has been subjected
to either physical or chemical treatment [22, 23]. TEWL was
measured in this study to determine the level of disruption to
skin barrier function following application of the MN arrays
during the study period. The Delfin VapoMeter® (Delfin
Technologies Ltd., Kuopio, Finland) is equipped with a closed
cylindrical chamber that contains sensors for relative humidity
and temperature. TheVapoMeter®was used tomeasure TEWL
at the application site (previously marked) pre- and post-
application of MAPs every day during the study. Before
TEWL measurement, each volunteer was rested for around
5 min to acclimatise to the ambient room temperature. TEWL
measurements were taken by carefully resting the Vapometer®
probe head perpendicular to the skin. After 20 s, TEWL read-
ings were recorded as the values presented on the digital display
unit of the VapoMeter®. TEWL readings were taken before the
application, immediately after removal and 18 h after removal
of MAPs to determine whether the skin barrier function had
returned to normal. On the last day of the study, a control patch
composed of Tegaderm™ adhesive dressing without
microneedle arrays attached was applied on the opposite arm
of the volunteer to evaluate its effect on the TEWL values.
Clinical scoring of skin irritation and erythema
Clinical scoring was used to determine whether skin irritation
or erythema occurred in any of the study volunteers. Clinical
scores were based on visual inspection following the scale
used for patch (contact allergy) testing according to the guide-
lines of the International Contact Dermatitis (ICD) Research
Group and the North American Contact Dermatitis Group
[24]. Clinical photographs of the skin before and after MAP
application were captured under controlled lighting conditions
by the Medical Photography Team at Belfast City Hospital.
Images were scored blindly by an experienced consultant der-
matologist. A clinical score for each test site was assigned,
using the ICD scores in Table 1.
ELISA protocols for biomarker quantification
in plasma samples
Potential systemic reactions to repeat MAP application were
evaluated by quantification of a range of key biomarkers before
and after the completion of the application/wear protocol. The
biomarkers studied were C-reactive protein (CRP), interleukin
1-β (IL-1β), tumour necrosis factor-α (TNF-α), immunoglob-
ulin G (IgG) and immunoglobulin E (IgE). Commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits were
used (Human total IgG Platinum ELISA quantification kit,
Affymetrix, Austria; Human IgE Platinum ELISA quantifica-
tion kit, Affymetrix, Austria; Human CRP instant ELISA quan-
tification kit, eBioscience, Austria; Human TNF-α ultrasensi-
tive ELISA quantification kit, Invitrogen Corporation, USA;
Human IL-1β Platinum ELISA quantification kit, Affymetix,
Austria), according to the manufacturers’ instructions. Plasma
samples were diluted using the sample diluents provided with
the kits. Plasma samples for the relevant ELISAs were diluted
as follows: CRP, 1:500; total IgG, 1:500,000; IgE, 1:10; IL-1β,
1:2 and TNF-α, 1:2.
The ELISA protocols for the kits were broadly the same.
Briefly, 96-well microplates were washed with the requisite
washing buffer before addition of the samples. Standards were
reconstituted, diluted and added, with the diluted plasma sam-
ples, to the plates. Plates were incubated at either room tem-
perature or 37 °C for 1 or 2 h to allow the binding of the
biomarker to the primary antibody. The wells on the plates
were then washed to remove any unbound antigen.
Detection antibody (100 μL) was added to the wells and the
microplates were incubated at room temperature with gentle
agitation for 1–2 h. The washing step was repeated and ali-
quots (100 μL) of diluted streptavidin-horse radish peroxidase
(HRP) were added to the wells, followed by incubation with
shaking for 30 min at room temperature. The washing step
was repeated. Substrate (100 μL) was then added to the wells
and the colorimetric reaction was terminated by the addition
of acid. Sample absorbance readings were recorded at 450 nm
on aMicroplate spectrophometer (FLOUstar™Omega, BMG
Labtech, Ortenberg, Germany).
Statistical analysis
Mathematical characterisation of the relationships between the
x and y variables in the representative calibration plots was
performed using least squares linear regression, following
analysis of residuals. Linearity was calculated by linear regres-
sion analysis. Means, standard deviation and RSD% were
calculated using Microsoft® Excel 2013 (Microsoft
Corporation, Redmond, WA, USA). Normality of the data
was tested using the Shapiro-Wilk test. Where appropriate,
statistical analyses to compare results were performed using
a paired t test analysis, Wilcoxon signed-rank test and one-
Table 1 ICD clinical scoring scale of patch testing
Score ICD
0 Negative reaction
+/− Doubtful reaction; faint erythema only
+ Weak (non-vesicular) positive reaction;
erythema infiltration and possibly papules
++ Strong (vesicular) positive reaction; erythema,
infiltration, papules, vesicles
+++ Extreme positive reaction; bullous reaction
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way analysis of variance (ANOVA), with post hoc compari-
sons performed using Tukey’s HSD test. In all cases, p < 0.05
denoted statistical significance. The statistical package
GraphPad Prism® Version 5.03 (GraphPad Software Inc.,
San Diego, CA, USA) was used for all statistical analysis.
Results
Volunteer recruitment
Eleven healthy volunteers (5 males and 6 females) aged be-
tween 24 and 39 years, with no pre-existing skin conditions
participated in the study, as presented in Table 2. Volunteers
were asked not to apply any cosmetic formulations on their
upper arms during the study period. The study was approved
by the School of Pharmacy’s Research Ethics Committee at
Queen’s University Belfast.
Skin disruption and recovery measurements
TEWLmeasurements were taken from the site of MAP appli-
cation for each volunteer before and after MAP application
every day during the study. Volunteers were rested for 5 min
before the measurement. To confirm complete recovery of
skin barrier function, measurements were also taken 18 h after
MAP removal. On the last day, a control patch comprised only
of Tegaderm™without microneedles was applied to each vol-
unteer on the opposite upper arm at the same time as the MAP.
Prior to MAP application, mean (± SD) TEWL values ranged
from 21.15 ± 5.1 to 26.31 ± 10.84 g h−1 m−2. As expected,
when MAPs were removed, the immediately measured
TEWL values increased significantly (p < 0.05 in all cases)
to values between 3 and 10 times the baseline values, as pre-
sented in Fig. 4. The increase on the first day, while signifi-
cant, was not as marked as on subsequent days, possibly due
to unmeasurable differences in ambient conditions in what
was not a temperature, ventilation or humidity controlled
room. On the third day, high standard deviation of
141.1 g h−1 m−2 was observed as one of the volunteers showed
a TEWL value of 495 g h−1 m−2. These high TEWL values
declined, reaching baseline values before the next application,
with no significant difference compared with the baseline val-
ue on the first day in all cases. Upon removal after 6 h, control
patches comprised of Tegaderm™ only, produced TEWL
values showed a non-significant (p = 0.0659) increase to
33.80 ± 7.16 g h−1 m−2 of the baseline value of 26.31 ±
10.84 g h−1 m−2 in the same day. This is expected, as
Tegaderm™ dressing application is not thought to have any
disrupting effect on the skin barrier function, given that it is a
vapour-permeable dressing.
Confirmation of MAP penetration using OCT and MAP
swelling using a digital microscope
To confirm the insertion and penetration of the microneedles
into the arms of the volunteers during the study, the researcher
applied the same patch to her own forearm on three different
occasions before the commencement of the study and record-
ed the penetration of MN into the skin by OCT imaging. The
OCT scan in Fig. 5 was taken immediately after MAP appli-
cation. It confirms that the microneedles punctured the stra-
tum corneum and extended approximately around 300 μm
into the skin. The diameter of the pores in the stratum
corneum induced by the microneedles was approximately
226 μm.
MAPs were visually inspected after removal from volun-
teers’ arms. Figure 6 A shows the elastic nature of the
microneedle array after absorbing interstitial fluid during the
6-h wear period. The arrays showed a curved centre, as a result
of the expected higher degree of swelling of the microneedles
as compared with the baseplate, as shown in Fig. 6B.
Microscope images confirmed that microneedle arrays were
flexible and elastic, as shown in Fig. 6C and D. It was noticed
that MN arrays remained intact without any loss or damage
after removal from the volunteers’ arms, as demonstrated in
Fig. 6E.
Microneedle array dimensions were studied before and af-
ter wear by calculating the distance between the first
microneedle and the last microneedle in the first rows (hori-
zontal and vertical) of the arrays. The mean change in array
dimensions post-removal was approximately 12.03 ± 3.43%.
Figure 7 shows an exemplar of the measurements before and
after the 6-h wear time.
Figure 7 shows exemplar digital images of MAPs at the
time of application and after 6 h of wear. It was very apparent
that the microneedles remained inserted, despite swelling and
the associated dimensional changes of the array, due to the
adhesive properties of the Tegaderm™.
Table 2 Demographic information of the human volunteers
Volunteers ID Gender Age (years) Ethnicity
V1 Male 28 Caucasian
V2 Female 28 Caucasian
V3 Male 26 Caucasian
V4 Male 29 Asian
V5 Male 39 Other/Arab
V6 Female 37 Other/Arab
V7 Male 28 Asian/Chinese
V8 Female 29 Caucasian
V9 Female 35 Asian
V10 Female 36 Other/Arab
V11 Female 24 Caucasian
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Fig. 4 Transepidermal water loss values measured before and after applyingMAPs. First day (A), second day (B), third day (C), fourth day (D), fifth day
(E). On all days, values increased significantly after MAP removal, but returned to baseline levels 18 h post-patch removal (means + SE, n = 11)
Fig. 5 Optical coherence
tomography image of MAP
immediately after insertion to the
forearm of the researcher. It is
clear that the MAP was able to
create pores and penetrate into the
skin upon manual application
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Clinical scoring of skin images before and after MN
patch application
Clinical photographs collected at random from four of the
volunteers before and after MAP application were scored by
visual inspection by an experienced Consultant Dermatologist
(DO’K), who was not informed how the skin hat been treated,
and an ICD score was assigned to each photograph (Table 3).
Figure 8 shows application sites before MAP application and
immediately after removal on the first day of study. Figure 9
shows application sites before MAP application and immedi-
ately after removal on the fifth day of study. It can be observed
Fig. 6 Digital images of MAPs
after removal from volunteers’
upper arms. Microneedles and
baseplates were flexible and
rubbery (A). The array centres
showed a higher degree of
swelling compared with the
baseplates (B). Microscope
images of swollen MAPs after
removal from a volunteer’s arm.
MAPs became elastic as a result
of imbibing interstitial fluid from
the volunteers (C, D). All of the
microneedles of every MAP were
removed intact, without any
deformation inside the skin (E)
Fig. 7 Microscope images of
MAPs showing the dimensions of
microneedle array (A) before and
(B) after application to human
volunteers. The area of the array
was calculated by measuring the
distance between the first and the
last microneedle of the first line in
the array in mm. Thus, the area
was calculated in mm2. The
application time was 6 h
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that clinical scores immediately after MAP removal ranged
between no erythema and mild erythema (Fig. 10).
However, as shown in Figs. 11, 18 h post-patch removal,
images showed either no erythema or dubious results. In all
cases, the erythema score was 0 (no erythema) before the fifth
application (approximately 42 h after the third application,
thus indicating full disappearance of erythema after that appli-
cation). Mild erythema was scored in volunteers 1 and 6 after
MAP removal on the fifth day, as shown in Fig. 10. Volunteer
9 did not show any erythematous reaction to MAPs after any
of the applications, as detailed in Table 3. Slight erythema was
visible, however, at the site of MAP application in most of the
Table 3 Dermatologist
evaluation of medical
photographs taken by medical
photographer of the upper arm of
volunteers after specified MAP
applications
Time of photograph capture Volunteer
1 male 5 males 6 females 9 females
Immediately before the first application (baseline) 0 0 0 0
Immediately after the first application +/− +/− +/− 0
18 h after fourth application +/− 0 +/− 0
Immediately before the fifth application 0 0 0 0
Immediately after the fifth application + +/− + 0
Fig. 8 Exemplar images of
MAPs immediately upon
application and after 6 h of wear.
Signs of interstitial fluid
absorption were noticed as
swelling at the centre of the
microneedle arrays in some
volunteers. The Tegaderm™
adhesive dressing permitted the
microneedles to stay in place over
the time of wear
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volunteers, as observed visually, immediately following the
removal of the MAPs. It was notable that any erythema ob-
served was directly related to the area of microneedle inser-
tion, rather than the border area where the adhesive
Tegaderm™ would have been in direct contact with skin.
Unlike any of the other 10 volunteers, one of the volunteers
showed a mild erythema at the site of one of the MAP appli-
cations after the completion of the study. However, this had
fully resolved upon follow-up 7 days later.
Five distinct biomarkers were quantified using ELISA kits
after separating plasma from blood samples. For clarity of data
presentation, each volunteer was assigned a distinctive colour
in analyses and the same colours were then used for the same
individual volunteers in the presentation of all analyses.
Calibration curves, constructed according to the manufac-
turers’ instructions, were used to calculate the levels of bio-
markers in the volunteers’ plasma samples. Values were
originally calculated in nanogram/millilitre, then corrected to
the ranges normally employed for each biomarker by account-
ing for the dilution factors of the samples.
CRP concentrations at the beginning and the end of the study
were determined, as presented in Fig. 12 I (A). There was no
significant difference in the mean levels of CRP between the
beginning and end of the study (p = 0.9658). The individual
volunteer CRP distribution is shown in Fig. 12 I (B). One vol-
unteer showed a significant change in their CRP plasma concen-
trations with 0.3 mg/L and 1.24 mg/L measured before and after
the study, respectively (marked in blue). However, this individ-
ual did not follow the trend of the other participants.
Figure 12 II depicts the levels of total IgG in volunteers’
plasma and indicates no significant difference (p = 0.3203)
between its level at the beginning and the end of the study.
All the measured values were within the normal ranges of IgG
in humans.
Fig. 9 Clinical photographs taken
of the upper arm skin of randomly
selected volunteers by a medical
photographer on the first day of
study. Photographs in the left
hand column were taken before
application of MAPs, while
photographs in the right hand
column were taken immediately
after patch removal (6-h wear
time). The area of patch
application was marked with a
pen
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Levels of IgE in plasma at the beginning and the end of the
study are presented in Fig. 12 III. Two volunteers recorded
values which did not follow the general trend of the other
volunteers (blue and light brown coloured points), but it was
noticed that they recorded approximately the same values be-
fore and after the study. Hence, the difference between the
mean values was not significant (p = 1.0000). This indicates
that repeat MAP application did not trigger allergic reactions
in any of the volunteers.
There was again no significant difference between the
levels of TNF-α in volunteers’ plasma samples taken at the
beginning and the end of the study (p = 0.7246), as demon-
strated in Fig. 12 IV. All values were within the normal range
found in the literature.
Results of the IL-1β ELISA showed that all the volunteers’
plasma levels were below the quantification limit of the kit.
Most of the absorbance results for volunteer samples approx-
imated those of the blank values. This indicates that plasma of
the volunteers contained undetectable levels of this particular
biomarker.
Discussion
The first patent on microneedle-based delivered systems was
filed in the 1970s [25], but it took more than 20 years before
the first practical demonstration [26]. Despite regularly being
hailed as a delivery system that will revolutionise drug and
vaccine delivery and patient monitoring/diagnosis, no true
microneedle product is currently marketed for medical indica-
tions. However, recent work by specialised microneedles
Fig. 10 Clinical photographs
taken bymedical photographer on
the fifth day of study.
Photographs in the left hand
column were taken before
application of MAPs, while
photographs in the right hand
column were taken immediately
after patch removal. It is notable
that erythema is directly centred
to the site of microneedle
insertion, rather than in the border
area where the adhesive was
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companies, contract pharmaceutical manufacturers and global
not for profit agencies has accelerated progress [27–30].
Regulatory approval and market authorisation of any med-
ical device or drug/vaccine product will always be ultimately
dependent upon demonstration of safety. In this respect,
microneedle systems have performed extremely well in all
reported scientific studies and clinical trials, with the only
adverse events ever seen being due to inappropriate use in
cosmetic treatments [31, 32]. Despite their mechanism of ac-
tion requiring the puncture of the skin’s protective stratum
corneum barrier, microneedles have been shown not to cause
infection, even when the skin is not pre-cleansed, whether the
microneedles themselves were sterilised or not [17, 31, 32].
Importantly, erythema and disruption in skin barrier function
caused by the initial skin puncture have also been shown to
resolve quickly, generally within less than 24 h for barrier
recovery and less than 7 days for erythema [1, 20, 21, 34].
There have been relatively few comprehensive clinical tri-
als of microneedle systems. Those that have been conducted
assessed safety only through skin appearance, absence of sig-
nificant adverse events and general assessments of patient
health. Being a vaccination study, the Prausnitz influenza
Fig. 11 Clinical photographs
taken after 18 h of MAP removal.
These images were taken on the
fifth day of study (i.e. after four
MAP applications; two to this
approximate site). Erythema
degree as assessed by the
dermatologist is assigned to each
image
Fig. 12 I: levels of plasma CRP at the beginning and the end of the study,
as determined using ELISA (means ± SE, n = 11) (A) and individual
volunteer values (B). II: levels of plasma IgG at the beginning and the
end of the study, as determined using ELISA (means ± SE, n = 11) (A)
and individual volunteer values (B). III: levels of plasma IgE at the
beginning and the end of the study, as determined using ELISA (means
± SE, n = 11) (A) and individual volunteer values (B). IV: levels of plas-
ma TNF-α at the beginning and the end of the study, as determined using
ELISA (means ± SE, n = 11) (A) and individual volunteer values (B). ns,
non-significant
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study involved only a single application to each volunteer, as
is typical for conventional influenza vaccination [35]. The
Zosano zolmitriptan study again involved only a single appli-
cation [36]. However, the Zosano parathyroid hormone study
involved multiple weekly applications [37]. None of these
studies reported any adverse event that raised concern. We
initially developed hydrogel-forming microneedle systems
for high-dose drug delivery and minimally invasive extraction
of skin interstitial fluid, with recent work now combining the
basic technology platform with plasmonic gold nanorods for
photothermal therapy of non-melanoma skin cancers. When
used for drug delivery or patient monitoring, this system is
likely to be used on a daily basis. Management of neoplastic
skin lesions may also require more than a single application.
Accordingly, while we have previously demonstrated that our
microneedle materials are biocompatible have inherent anti-
microbial properties and that the microneedles themselves can
reproducibly be inserted into their own skin by human volun-
teers without adverse events, the critical next step in transla-
tion is to comprehensively demonstrate that repeat application
is safe. Our initial work in immunocompetent nude mice
showed that repeated application and wear of our hydrogel-
forming microneedles generated only mild erythema that
quickly resolved upon patch removal, as did disruption of skin
barrier function, as determined by measuring transepidermal
water loss [19]. Key biomarkers were not disturbed by
microneedle use. In the present study, our focus has, for the
first time, been on repeat application in human volunteers.
To mimic the normal use of a transdermal patch or patient
monitoring system, we alternated the site of MAP application
over the 5-day study period here. Thus, we studied skin ap-
pearance and skin barrier function, as exemplified by TEWL,
at two approximate sites on the upper arms of the 11 human
volunteers. TEWL readings showed the expected trend, in that
they were significantly increased immediately after MAP re-
moval, but then returned to normal when next measured.
Within the general trend, TEWL values showed considerable
intra- and inter-individual variability between the volunteers
on each day of the study. Such variability may be attributable
to unmeasured differences in environmental factors such as
humidity, temperature or ventilation [38, 39], in addition to
some intrinsic factors, such as the physical, thermal or emo-
tional sweating of participants [40], differences in degree of
activity or diet over the duration of the study [23]. From a
safety standpoint, it is desirable for the created pores to close
soon after microneedle removal to prevent permeation of un-
desired substances or pathogenic microorganisms [41]. The
pores are expected to close as a physiological response, due
to the skin’s natural repair mechanisms [42]. Upon disruption
of the stratum corneum barrier, lamellar body secretion is
immediately initiated, followed by synthesis of lipids to re-
store and maintain the barrier [43]. In general, the time taken
for this “healing” process depends upon the initial degree of
barrier disruption which, in turn, depends on the geometry and
dimensions of the microneedle array employed, as well as the
length of time the needles array remains inserted in the skin
[44]. In the present study, it was shown that skin barrier func-
tion had always returned to their normal baseline values when
next measured, which was approximately 18 h post-MAP re-
moval. However, according to previous studies performed
using our hydrogel-forming microneedle arrays, along with
the vast body of evidence on skin barrier recovery following
microneedle removal, it is believed that the time required for
the skin to reach its normal state would actually be much
shorter.
Erythema was investigated to determine potential for local
skin irritation, associated with multiple MAP applications. It
is crucial to determine the potential irritant effects of
microneedles as part of safety assessments of these devices
and indeed for any material that is intended to stay in contact
with the skin over prolonged periods of time [45]. This is
important, as dysfunction of skin barrier, as shown by
TEWL studies, is a primary event in development of atopic
dermatitis and other ongoing skin disorders [46]. In the pres-
ent study, clinical scores after treatment were graded from “no
erythema” to “severe erythema” using the International
Contact Dermatitis Research Group (ICDRG) criteria. In most
volunteers, a certain degree of skin erythema was observed
immediately after MAP removal. However, this markedly de-
creased or disappeared when examined 18 h later, indicating
that any erythema was short lived. The effects observed are in
agreement with other studies that showed any skin irritation
caused by microneedle application was short lived, as con-
firmed by laser Doppler imaging [47] or chromametry [22].
In addition, Wermeling et al. [48] found that erythema caused
by microneedle insertion was transient and disappeared after a
few hours. Arya et al. [34] showed that mild erythema local-
ised to the site of patch application resolved fully within
7 days. This matches what we saw here in the one volunteer
who had mild erythema at one of the MAP application sites
beyond the study period, but not for longer than 1 week.
Importantly, in the present study, there were no cases where
erythema reached moderate or severe scores, even after mul-
tiple applications.
It is abundantly clear that skin application of microneedle
systems can induce pronounced systemic immune responses,
as evidenced by the plethora of published literature on
microneedle vaccines [12, 33, 35]. Elevated biomarker levels
can also be used to assess, for example skin injury or infection.
Indeed, Li et al. [49] used the EIIIA+ (526 bp) segment, a very
sensitive marker of tissue injury, to show that rat skin pre-
treated with super-short 80-μm microneedle arrays and sub-
sequently incubated with an applied culture of Staphylococcus
aureus was not infected. This study also assessed develop-
ment of infection by measuring the levels of white blood cells,
leukomonocytes and neutrophile granulocyte within the
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blood. It was demonstrated that there was no significant dif-
ference in the populations of three cell types between the
microneedle-treated group and an untreated group, confirming
that infection did not occur.
We repeatedly applied polymeric microneedle arrays (sep-
arately, dissolving and hydrogel-forming microneedle arrays)
to immunocompetent nude hairless mice over 3–5 weeks [19].
CRP, total IgG, IL-1β and TNF-α biomarkers were studied,
with plasma levels of these biomarkers shown to never be
statistically different from untreated controls. The present
study represents the first time that biomarkers indicative of
safety have been studied in humans following microneedle
application.
CRP is a highly conserved plasma protein that is released
by the liver into the vascular circulation to activate the com-
plement system. Measuring CRP is perhaps the most practical
way to detect and monitor the presence and progress of a
systemic inflammatory response due to its rapidity of re-
sponse, short half-life and relative simplicity of measurement
[50]. CRP is stable in serum or plasma and is typically used to
diagnose infection and sepsis [51]. Normal CRP levels are
between is 0 and 5 mg/L [52]. CRP levels present may be
raised dramatically within 72 h due to infection [53]. The data
obtained in the present study strongly suggest that no infec-
tions occurred, as levels of CRP were within the normal levels
with no significant changes noticed over the course of the
experimental period. IL-1β is a key member of the interleukin
family, which modulates the inflammation caused by bacterial
and viral infections [54]. It is mainly produced by the cells of
the innate immune system. However, some of the epithelial
cells of the skin can express IL-1β, which explains the expres-
sion of this factor in psoriatic disease states [55]. Samples used
in the IL-1β ELISAwere quantified in diluted and undiluted
states, in order to ensure that all levels, including those of neat
plasma samples, were below the detection limits of the system
employed. Results indicated that all samples were below the
detection limits. The detection limit was 0.3 pg/mL, according
to the manufacturer’s instructions. TNF-α is released by dif-
ferent types of immune cells to mediate the events involved in
inflammation and infection. Thus, it plays a crucial role in the
defence against fungi, bacteria and parasites by regulating the
proliferation of T-cells [56]. TNF-α levels were below 2 pg/
mL in all volunteers, which agreed with the normal levels
found in the literature, in which the range was between 0.0
and 32.5 pg/mL [57]. IgG is one of the most abundant proteins
in human serum, accounting for about 10–20% of plasma
proteins. It is the major class of the five classes of immuno-
globulins in human beings, as it accounts for about 75% of the
total immunoglobulins in the plasma of healthy individuals
[58]. IgG antibodies have a relatively high affinity and can
persist in the circulation for a long time [59]. Total IgG levels
were found to be within the normal human adult range of 639–
1.349 mg/dL [60]. It should be noted, of course, that IgG
levels can often take weeks or months to peak, with the rela-
tively short duration of the present study precluding determi-
nation of any delayed rise, however, unlikely. IgE is a type of
antibody synthesised by plasma cells in mammals. It is iden-
tified as the key molecule in mediating what are described as
type-1 hypersensitivity reactions (allergic asthma, allergic rhi-
nitis, food allergy, atopic dermatitis, some forms of drug aller-
gy and insect sting allergy) [61]. It is the least expressed im-
munoglobulin compared with the other types of immunoglob-
ulins [62]. Increased levels of IgE in the blood trigger a cas-
cade of events that cause allergic contact urticaria, a hypersen-
sitivity reaction manifested by immediate but transient local-
ised swelling and redness that occurs in the skin after direct
contact with an offending substance [63]. In the present study,
all volunteers showed IgE levels below 500 ng/mL. Literature
studies have stated that IgE is normally present in plasma at a
concentration of less than 1 μg/mL [64]. Accordingly, an al-
lergic reaction was not seen in this study.
This study serves to demonstrate the initial safety of
prolonged hydrogel-forming MAP application by assessing
basic immunological markers known to be elevated in both
skin and systemic immune responses, infection, inflammation
and allergy. It is worth noting that further, more detailed, im-
munochemical analysis is now needed to evaluate the long-
term serological impact, if any, of repeated and prolonged
application of hydrogel-forming MAPs to the skin and indeed
to the body when MAPs are used clinically or periods of
weeks and months.
Conclusion
The present study complements an already strong body of
evidence on the safety of hydrogel-forming microneedle array
technology. We have shown, for the first time, in human vol-
unteers that repeat application and wear of these microneedles
does not cause any prolonged skin reactions or disruption of
skin barrier function and does not disturb the normal balance
of key systemic biomarkers of inflammation, infection, allergy
or immunity over a fixed study period.
Conclusions about the impact of repeat application/wear of
microneedles prepared from other materials cannot be appro-
priately drawn from this work, however. We are currently
working towards CE marking of our hydrogel-forming
microneedle array technology as a medical device.
Development of the technology as a drug or combination
product will further require demonstration that intradermal
administration of a drug of interest does not cause any adverse
event not seen with conventional routes of administration, in
addition to showing acceptable pharmacokinetics and phar-
macodynamics. This will need to be done on a case-by-case
basis.
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